Tech Company Financing Transactions
Light Horse Therapeutics Funding Round
On 1/9/2025, Light Horse Therapeutics raised $62 million in Series A financing from AbbVie Biotech Ventures, Bristol-Myers Squibb and Mubadala.
Transaction Overview
Company Name
Announced On
1/9/2025
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series A
Proceeds Purpose
The new biotech plans to apply precision genome editing to small-molecule drug discovery with an initial focus on cancer targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Diego, CA Undisclosed
USA
San Diego, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Light Horse is leading the way in precision gene editing applied to small molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that play critical roles in disease biology. Our initial focus addresses high-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Markus Renschler
Browse more venture capital transactions:
Prev: 1/9/2025: Nevermined venture capital transaction
Next: 1/9/2025: A2 Biotherapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs